<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426920</url>
  </required_header>
  <id_info>
    <org_study_id>IOV/QD001</org_study_id>
    <nct_id>NCT00426920</nct_id>
  </id_info>
  <brief_title>Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler</brief_title>
  <official_title>Evaluation of the Pharmacokinetics and Pharmacodynamics of Spray-Dried Recombinant Human Insulin Powder for Inhalation Administered Via a Dry Powder Inhalation Device Relative to SC Recombinant Human Insulin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QDose Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QDose Limited</source>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacokinetics and pharmacodynamics of different doses of spray-dried
      recombinant human insulin powder for inhalation administered via a dry powder uinhalation
      device compared with subcutaneously administered regular human insulin in healthy male
      volunteers under the conditions of a eugycemic clamp.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explorative, single-center, randomized, open label, 4-way crossover study to evaluate the
      pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human
      insulin powder for inhalation administered via a dry powder uinhalation device compared with
      subcutaneously administered regular human insulin in healthy male volunteers under the
      conditions of a eugycemic clamp.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum insulin serum concentration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>early T50%</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>late T50%</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum glucose infusion rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early T50%</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late T50%</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
  </secondary_outcome>
  <enrollment>14</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  non smoking for at least 12 months

          -  BMI equal to or less than 28

          -  no clinically significant abnormalities

          -  FVC and FEV1 equal to or more than 80%

          -  willing to participate and to sign informed consent form

        Exclusion Criteria:

          -  positive results for insulin antibodies at screening

          -  history of substance abuse or dependency within last 5 years

          -  positive screening test for substance abuse

          -  positive blood test for HIV, hepatitis B or hepatitis C antibody

          -  fasting blood glucose of more than 126mg/dl

          -  any existing medical conditions which might interfere with absoprtion, distribution,
             metabolism or excretion of study medication

          -  history of bronchospastic disease(asthma), tachycardia, migraine headache,
             hypoglycemic episodes, jaundice, liver diseases, arterial hemorrhaging, severe
             hypertension or hypotension, cardiac abnormality, renal disease, allergies, unresolved
             psychiatric illness, drug-induced myopathy or any other clinically significant
             abnormality

          -  has received investigational medications within 21 days prior to receiving the first
             dose of study medication

          -  has taken or used any prescription medications within 21 days prior to receiving the
             first dose of study medication

          -  has taken or used any OTC medications,vitamins or herbal and/or nutritional
             supplements within 10 days days prior to receiving the first dose of study medication

          -  health that may be adversely affected by procedures or medications used in the study

          -  unwillingness or inability to understand or to follow required study restrictions and
             procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Hompesch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research Incorporated</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus Hompesch, MD</last_name>
    <phone>619-427-1300</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>24-hour emergency number</last_name>
    <phone>619-409-1277</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research Incorporated</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus hompesch, MD</last_name>
      <phone>619-427-1300</phone>
    </contact>
    <contact_backup>
      <last_name>24-hour emergency number</last_name>
      <phone>619-409-1277</phone>
    </contact_backup>
    <investigator>
      <last_name>Marcus Hompesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2007</study_first_submitted>
  <study_first_submitted_qc>January 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2007</study_first_posted>
  <last_update_submitted>January 24, 2007</last_update_submitted>
  <last_update_submitted_qc>January 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2007</last_update_posted>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>inhaled</keyword>
  <keyword>recombinant human insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

